Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OST11098
- Development stage
- Preclinical
- Lead developer
- Open Source Therapeutics
01
Overview
OST11098: sourced facts only. name: "In this study, we introduce OST11098, a newly identified, orally bioavailable, selective, and potent CYP11A1 inhibitor with demonstrated anti-tumor efficacy against NHA resistance." [DOI:10.1158/1538-7445.am2025-1777]; target: "In this study, we introduce OST11098, a newly identified, orally bioavailable, selective, and potent CYP11A1 inhibitor with demonstrated anti-tumor efficacy against NHA resistance." [DOI:10.1158/1538-7445.am2025-1777]; developer: "Open Source Therapeutics, Suzhou, China." [DOI:10.1158/1538-7445.am2025-1777]; stage: "In a VCaP CRPC xenograft mouse model, OST11098 demonstrated significant anti-tumor efficacy." [DOI:10.1158/1538-7445.am2025-1777]
02
Targets
CYP11A1 (Cholesterol side chain cleavage enzyme)
Beyond the preview
Go deeper on OST11098.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OST11098.